• linkedin
  • Increase Font
  • Sharebar

    9 Newly Approved Novel Drugs

    It's been a busy year for the FDA.


    Old Woman clutching cane

    7. Xadago (safinamide), Newron Pharmaceuticals

    Indications: A monoamine oxidase type B (MAO-B) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.

    Dosage: Initial dosage is 50 mg PO daily. After 2 weeks, may increase dose to 100 mg PO daily , based on individual need and tolerability.

    Contraindications: Severe hepatic impairment or hypersensitivity to the active substance or to any of the excipients. Coadministration with other MAOIs; opioids; St John’s wort, or tricyclic, tetracyclic, or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate or amphetamine and their derivatives; Dextromethorphan; or selective norepinephrine reuptake inhibitors.

    Read the FDA statement here

    Read the full prescribing information here

    Previous ButtonNext Button



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available